Biomarin Pharmaceutical Sees FY23 EPS $1.85-$2.10 Vs $1.02 Est; FY23 Revenue $2.375B-$2.5MB Vs 2.46B Est
Portfolio Pulse from Benzinga Newsdesk
Biomarin Pharmaceutical has projected its FY EPS to be between $1.85 and $2.10, higher than the estimated $1.02. The company also expects its FY23 revenue to be between $2.375B and $2.5B, slightly lower than the estimated $2.46B.
July 31, 2023 | 8:28 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Biomarin Pharmaceutical's higher than expected EPS forecast could positively impact its stock price. However, the lower than expected revenue forecast for FY23 might offset this positive impact.
The company's EPS forecast is significantly higher than estimates, which could lead to a positive reaction from investors. However, the lower than expected revenue forecast for FY23 could cause some concern, potentially offsetting any gains from the EPS news.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100